Novel patented therapeutic approaches targeting the 37/67 kDa laminin receptor for treatment of cancer and Alzheimer's disease

Expert Opinion on Therapeutic Patents
Katarina JovanovicStefan F T Weiss

Abstract

The 37/67 kDa high-affinity laminin receptor (laminin receptor precursor/laminin receptor, LRP/LR) is a multi-faceted cellular receptor. It plays a vital role in the malignancy of various cancer types where it is seen to contribute to invasion, adhesion, apoptosis evasion and angiogenesis. Furthermore, it has been found to play an important role in facilitating the processes leading to neurotoxicity in Alzheimer's disease (AD). Various therapeutic options targeting this receptor have been patented with the outlook on application for the treatment/prevention of these diseases. The various roles that LRP/LR plays in cancer, AD and infectious diseases caused by viruses and bacteria have been examined in detail and an overview of the current patented therapeutic strategies targeting this receptor is given. Molecular tools directed against LRP/LR, such as antibodies and small interfering RNA, could prove to be effective in the prevention of metastasis and angiogenesis while inducing apoptosis in cancers. Moreover, these strategies could also be applied to AD where LRP/LR is seen to facilitate the production and internalization of the neurotoxic Aβ peptide. This review provides a comprehensive overview of the mechanisms by which LRP/...Continue Reading

References

Mar 29, 1983·Biochemical and Biophysical Research Communications·N C RaoL A Liotta
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F A van den BrûleV Castronovo
Feb 1, 1997·Endocrine Reviews·N Ferrara, T Davis-Smyth
Aug 20, 1997·Journal of the National Cancer Institute·D WaltregnyV Castronovo
Jan 8, 1999·Biochemical and Biophysical Research Communications·K KinoshitaA Hoffmann
Feb 19, 1999·Cancer·M NadjiA R Morales
Apr 30, 1999·Science·S Artavanis-TsakonasR J Lake
Feb 26, 2000·Carcinogenesis·S W Lowe, A W Lin
Aug 30, 2000·Nature·C M PerouD Botstein
Oct 26, 2000·Nature·M O Hengartner
Jun 29, 2002·Science·John D HoodDavid A Cheresh
Sep 3, 2002·Advanced Drug Delivery Reviews·Irène BriggerPatrick Couvreur
Oct 26, 2002·Cancer Cell·Jerry W Shay, Woodring E Wright
Jan 14, 2003·Trends in Molecular Medicine·Andrew R ReynoldsKairbaan Hodivala-Dilke
Aug 23, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Manfred OgrisErnst Wagner
Sep 27, 2003·Clinical Therapeutics·Rony Abou-JawdeTarek Mekhail
Dec 21, 2004·Nature Neuroscience·James P ClearyKaren H Ashe
Mar 12, 2005·CA: a Cancer Journal for Clinicians·D Max ParkinPaola Pisani
Aug 8, 2006·Molecular Cancer Therapeutics·Maria Antonietta CeroneChantal Autexier
Nov 18, 2006·Cell·Gaorav P Gupta, Joan Massagué
Apr 25, 2007·Biochimica Et Biophysica Acta·Laura WestergardDavid A Harris
Apr 9, 2008·Physiological Reviews·Rafael LindenRicardo R Brentani
Apr 22, 2008·Cellular & Molecular Biology Letters·Tharinee Susantad, Duncan R Smith

❮ Previous
Next ❯

Citations

Oct 21, 2015·Journal of Alzheimer's Disease : JAD·Emma C PinnockStefan F T Weiss
Jan 26, 2017·Experimental Cell Research·Carmelle MunienStefan F T Weiss
Dec 13, 2017·Toxicology Mechanisms and Methods·Xiao ChenJianjun Liu
Oct 2, 2015·PloS One·Thandokuhle KhumaloStefan F T Weiss
Nov 15, 2019·Expert Opinion on Therapeutic Patents·Leila VaniaStefan F T Weiss
Nov 22, 2017·Oncotarget·Tyrone C OtgaarStefan F T Weiss
Jun 28, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ming FuAnkush Gosain
Jun 23, 2020·Journal of Alzheimer's Disease : JAD·Katelyn CuttlerStefan F T Weiss
Mar 8, 2020·International Journal of Molecular Sciences·Antaripa BhattacharyaDaniela Sarnataro
May 14, 2019·Journal of Alzheimer's Disease : JAD·Monique J BignouxStefan F T Weiss

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Related Papers

Frontiers in Bioscience (Landmark Edition)
Vusi MbazimaStefan F T Weiss
Expert Opinion on Therapeutic Patents
Paolo De Paoli
Sheng li ke xue jin zhan [Progress in physiology]
Q Y Zhang
© 2022 Meta ULC. All rights reserved